Market Cap 11.56B
Revenue (ttm) 2.85B
Net Income (ttm) 426.86M
EPS (ttm) N/A
PE Ratio 21.30
Forward PE 20.85
Profit Margin 14.96%
Debt to Equity Ratio 0.00
Volume 1,181,100
Avg Vol 3,144,572
Day's Range N/A - N/A
Shares Out 192.11M
Stochastic %K 70%
Beta 0.30
Analysts Strong Sell
Price Target $89.74

Company Profile

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic pep...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 506 6700
Address:
770 Lindaro Street, San Rafael, United States
IN0V8
IN0V8 Dec. 26 at 6:57 PM
$BMRN Buy Truist Securities raises target price to $100 from $80
0 · Reply
FiscalStimulusF
FiscalStimulusF Dec. 26 at 3:28 PM
$BMRN Conditions are shifting toward markets rewarding operational proof over narrative ambition. Capital allocation choices will reveal true priorities. Demonstrated durability would lengthen investor time horizons. Upside remains tied to tangible progress, not assumptions.
1 · Reply
DairyQueen505
DairyQueen505 Dec. 26 at 2:35 AM
$BMRN BMN 351 clinical update next week. Positive update will send shares higher. Also expecting institutional ownership to increase with big boys rotating in at end/beginning of the year. This is a growth company now with the recent acquisition - time for a multiple expansion.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 2:28 PM
Actionable Trade Alert for $BMRN: Market Context: $BMRN closed at $60.16, showing strength as it approaches the 60D high of $63.89. The RSI of 67.95 indicates the stock is nearing overbought territory, suggesting caution but also potential for upward momentum. The MA30 (54.76) and MA50 (54.08) are both below the current price, indicating a bullish trend. Directional Bias: The stock is in a bullish phase, supported by the proximity to recent highs and the upward trend indicated by moving averages. However, the elevated RSI suggests a potential pullback could occur. Trade Plan: - Suggested Entry: $60.50 (slightly above the last close) - Stop Loss: $57.50 (2.65% below entry) - Take Profit Targets: 1. $63.00 (4.13% gain) 2. $65.00 (7.19% gain) 3. $70.50 (16.57% gain) With a focus on the high-low range and moving averages, this plan targets a minimum of 17% ROI on the final target. https://privateprofiteers.com
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 24 at 9:17 PM
$BMRN RSI: 67.95, MACD: 1.2983 Vol: 3.06, MA20: 54.92, MA50: 54.08 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
1iquid
1iquid Dec. 24 at 8:01 PM
💎 Liquid® Live Actionable Trade Asset: $BMRN Contracts: $BMRN January 15, 2027 $60 Calls Scale in: $9.54- $11.66 Scale out: $37.10-$63.60 Profit Potential : 342% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
DairyQueen505
DairyQueen505 Dec. 24 at 1:40 PM
$BMRN expecting an 8k to drop any day now with clinical update on BMN 351. Going to $100.
0 · Reply
DairyQueen505
DairyQueen505 Dec. 23 at 5:37 PM
$BMRN @buddahbob @traditbetit where did they say they would release results by EoY?
0 · Reply
tradeitbetit
tradeitbetit Dec. 23 at 4:34 PM
$BMRN 3 more trading days to meet their BMN 351 results release timeline. #DMD patients should be the big winners here alongside the news from $CAPR because $SRPT s therapy is sadly insufficient
2 · Reply
JarvisFlow
JarvisFlow Dec. 23 at 1:08 PM
Truist Securities updates rating for BioMarin Pharmaceutical ( $BMRN ) to Buy, target set at 80 → 100.
0 · Reply
Latest News on BMRN
What's Going On With BioMarin Stock On Tuesday?

Dec 23, 2025, 1:05 PM EST - 4 days ago

What's Going On With BioMarin Stock On Tuesday?


BioMarin: Amicus Buyout Sparks My Enthusiasm

Dec 22, 2025, 3:15 PM EST - 4 days ago

BioMarin: Amicus Buyout Sparks My Enthusiasm

FOLD


BioMarin Pharmaceutical Inc. (BMRN) M&A Call Transcript

Dec 19, 2025, 11:27 AM EST - 8 days ago

BioMarin Pharmaceutical Inc. (BMRN) M&A Call Transcript


BioMarin to Buy Amicus Therapeutics for $4.8 Billion

Dec 19, 2025, 8:13 AM EST - 8 days ago

BioMarin to Buy Amicus Therapeutics for $4.8 Billion

FOLD


BioMarin to acquire Amicus Therapeutics for $4.8 Billion

Dec 19, 2025, 7:56 AM EST - 8 days ago

BioMarin to acquire Amicus Therapeutics for $4.8 Billion

FOLD


BioMarin Pharmaceuticals - Growing Numbers, Falling Expectations

Oct 28, 2025, 6:58 AM EDT - 2 months ago

BioMarin Pharmaceuticals - Growing Numbers, Falling Expectations


BioMarin Pharma plans to divest struggling gene therapy

Oct 27, 2025, 6:34 PM EDT - 2 months ago

BioMarin Pharma plans to divest struggling gene therapy


BioMarin to Participate in Upcoming Investor Conferences

Aug 27, 2025, 9:00 AM EDT - 4 months ago

BioMarin to Participate in Upcoming Investor Conferences


BioMarin Announces Completion of Acquisition of Inozyme

Jul 1, 2025, 8:45 AM EDT - 6 months ago

BioMarin Announces Completion of Acquisition of Inozyme

INZY


Why Is BioMarin Stock Trading Higher On Thursday?

Feb 20, 2025, 9:39 AM EST - 11 months ago

Why Is BioMarin Stock Trading Higher On Thursday?


IN0V8
IN0V8 Dec. 26 at 6:57 PM
$BMRN Buy Truist Securities raises target price to $100 from $80
0 · Reply
FiscalStimulusF
FiscalStimulusF Dec. 26 at 3:28 PM
$BMRN Conditions are shifting toward markets rewarding operational proof over narrative ambition. Capital allocation choices will reveal true priorities. Demonstrated durability would lengthen investor time horizons. Upside remains tied to tangible progress, not assumptions.
1 · Reply
DairyQueen505
DairyQueen505 Dec. 26 at 2:35 AM
$BMRN BMN 351 clinical update next week. Positive update will send shares higher. Also expecting institutional ownership to increase with big boys rotating in at end/beginning of the year. This is a growth company now with the recent acquisition - time for a multiple expansion.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 2:28 PM
Actionable Trade Alert for $BMRN: Market Context: $BMRN closed at $60.16, showing strength as it approaches the 60D high of $63.89. The RSI of 67.95 indicates the stock is nearing overbought territory, suggesting caution but also potential for upward momentum. The MA30 (54.76) and MA50 (54.08) are both below the current price, indicating a bullish trend. Directional Bias: The stock is in a bullish phase, supported by the proximity to recent highs and the upward trend indicated by moving averages. However, the elevated RSI suggests a potential pullback could occur. Trade Plan: - Suggested Entry: $60.50 (slightly above the last close) - Stop Loss: $57.50 (2.65% below entry) - Take Profit Targets: 1. $63.00 (4.13% gain) 2. $65.00 (7.19% gain) 3. $70.50 (16.57% gain) With a focus on the high-low range and moving averages, this plan targets a minimum of 17% ROI on the final target. https://privateprofiteers.com
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 24 at 9:17 PM
$BMRN RSI: 67.95, MACD: 1.2983 Vol: 3.06, MA20: 54.92, MA50: 54.08 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
1iquid
1iquid Dec. 24 at 8:01 PM
💎 Liquid® Live Actionable Trade Asset: $BMRN Contracts: $BMRN January 15, 2027 $60 Calls Scale in: $9.54- $11.66 Scale out: $37.10-$63.60 Profit Potential : 342% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
DairyQueen505
DairyQueen505 Dec. 24 at 1:40 PM
$BMRN expecting an 8k to drop any day now with clinical update on BMN 351. Going to $100.
0 · Reply
DairyQueen505
DairyQueen505 Dec. 23 at 5:37 PM
$BMRN @buddahbob @traditbetit where did they say they would release results by EoY?
0 · Reply
tradeitbetit
tradeitbetit Dec. 23 at 4:34 PM
$BMRN 3 more trading days to meet their BMN 351 results release timeline. #DMD patients should be the big winners here alongside the news from $CAPR because $SRPT s therapy is sadly insufficient
2 · Reply
JarvisFlow
JarvisFlow Dec. 23 at 1:08 PM
Truist Securities updates rating for BioMarin Pharmaceutical ( $BMRN ) to Buy, target set at 80 → 100.
0 · Reply
notreload_ai
notreload_ai Dec. 23 at 12:20 PM
Oppenheimer initiates coverage of $SPRB with an Outperform rating, citing strong FDA signals, accelerated approval potential, and possible acquisition interest from $BMRN https://notreload.xyz/oppenheimer-starts-coverage-on-spruce-biosciences-with-bullish-outlook/
0 · Reply
ZacksResearch
ZacksResearch Dec. 22 at 5:35 PM
$BMRN makes a bold $4.8B move — is this a rare-disease power play? 💰🧬 BioMarin agreed to acquire $FOLD for $4.8B, adding two growing rare disease drugs and a late-stage pipeline asset to strengthen its portfolio. That’s immediate scale plus future optionality in one deal. Full deal breakdown and what it means for both stocks 👉 https://www.zacks.com/stock/news/2807526/biomarin-to-buy-rare-disease-drugmaker-amicus-therapeutics-for-48b?cid=sm-stocktwits-2-2807526-teaser-25832&ADID=SYND_STOCKTWITS_TWEET_2_2807526_TEASER_25832
0 · Reply
svk33
svk33 Dec. 22 at 5:17 PM
$BMRN 59.20 is the 1/3 fib retrace lvl. lets see what happens here
1 · Reply
tradeitbetit
tradeitbetit Dec. 22 at 5:07 PM
$BMRN this turd needs viagra….. cant hold it up for long
0 · Reply
ZacksResearch
ZacksResearch Dec. 22 at 4:35 PM
$BMRN makes a big move with $FOLD acquisition! 💥 BioMarin is acquiring Amicus Therapeutics for $4.8B, boosting its rare disease portfolio with Galafold and Pombiliti-Opfolda. This strategic deal, expected to close in Q2 2026, is expected to be accretive within the first 12 months post-closure. 📈 Discover how this deal could reshape BMRN's future here 👉 https://www.zacks.com/stock/news/2807526/biomarin-to-buy-rare-disease-drugmaker-amicus-therapeutics-for-48b?cid=sm-stocktwits-2-2807526-body-25834&ADID=SYND_STOCKTWITS_TWEET_2_2807526_BODY_25834
0 · Reply
tradeitbetit
tradeitbetit Dec. 22 at 3:46 PM
$BMRN prioritization, if this happened they might be focusing their resources because BMN 351 was such a benefit to the patient. Assuming a lot but would make sense, I guess we will see soon after “sitting tight”
0 · Reply
TrendGlowX_1441
TrendGlowX_1441 Dec. 22 at 3:31 PM
$BMRN under the radar large biotech, if it breaks the base with volume ignition it can trend clean without noise
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 22 at 3:20 PM
0 · Reply
biotech
biotech Dec. 22 at 2:56 PM
$SGMO's Fabry disease gene therapy has potential to be #once and done $FOLD GALAFOLD only addresses certain mutations. $SGMO GT has potential to address a #larger patient #population compared to #Galafold. KOL doesnt like $BMRN $FOLD galafold for severe patience
1 · Reply
biotech
biotech Dec. 22 at 2:31 PM
0 · Reply
JarvisFlow
JarvisFlow Dec. 22 at 11:59 AM
HC Wainwright & Co. has adjusted their stance on BioMarin Pharmaceutical ( $BMRN ), setting the rating to Neutral with a target price of 55 → 60.
0 · Reply
tradeitbetit
tradeitbetit Dec. 22 at 2:32 AM
$BMRN $FOLD $SGMO wow what an acquisition
1 · Reply